Regarding osteopontin alone as a marker, it was demonstrated in a different study that it performs better than AFP (AUROCs of 0.85 and 0.68, respectively), a benefit that remained for early-stage HCC; this is further discussed below [26]. Here, AFP is linked to hepatocellular carcinoma.